Minireviews
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Oct 26, 2024; 16(10): 550-563
Published online Oct 26, 2024. doi: 10.4330/wjc.v16.i10.550
Sodium glucose cotransporter 2 inhibitors in the management of heart failure: Veni, Vidi, and Vici
Monika Bhandari, Akshyaya Pradhan, Pravesh Vishwakarma, Abhishek Singh, Rishi Sethi
Monika Bhandari, Akshyaya Pradhan, Pravesh Vishwakarma, Abhishek Singh, Rishi Sethi, Department of Cardiology, King Georg’s Medical University, Lucknow 226003, Uttar Pradesh, India
Author contributions: Bhandari M and Pradhan A conceived the project, performed the literature review, revised the manuscript based on the comments, and prepared the revised version; Vishwakarma P and Singh A wrote the draft manuscript; Sethi R critically reviewed the manuscript; Vishwakarma P made the figures; Singh A was responsible for the bibliography; Sethi R supervised the table construction; Pradhan A submitted the manuscript to the journal.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Akshyaya Pradhan, FACC, FCCP, FESC, MBBS, MD, Professor, Department of Cardiology, King Georg’s Medical University, Shahmina Road, Chowk, Lucknow 226003, Uttar Pradesh, India. akshyaya33@gmail.com
Received: March 31, 2024
Revised: August 25, 2024
Accepted: September 6, 2024
Published online: October 26, 2024
Processing time: 200 Days and 5.7 Hours
Core Tip

Core Tip: Heart failure (HF) is associated with high morbidity and mortality rates. Sodium glucose cotransporter-2 inhibitors (SGLT-2is) are approved for diabetes mellitus (DM), and have also demonstrated improvement in renal and cardiovascular (CV) outcomes along with good glycemic control. Two landmark studies of SGLT-2is in patients with HF demonstrated improvement in HF hospitalization and CV mortality, irrespective of DM status. Subsequent clinical trials proved that SGLT-2is also benefit patients with HF with preserved ejection fraction with/without DM. Emerging positive data for SGLT-2is in acute HF and post-myocardial infarction scenarios have bolstered their pivotal role in the full diapason of HF.